^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen:ICE
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/20/2021
    Excerpt:
    Diffuse large B-Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY…Preferred Regimens…ICE (ifsofamide, carboplatin, etoposide) ± rituximab